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Recent findings in the past two decades have brought many insights into the biology of thyroid benign and
malignant lesions, in particular the papillary and follicular thyroid cancers. Although, much progress have been
made, thyroid cancers still pose diagnostic problems regarding differentiation of follicular lesions in relation to their
aggressiveness and the treatment of advanced and undifferentiated thyroid cancers. Metallothioneins (MTs) were
shown to induce cancer cells proliferation, mediate resistance to apoptosis, certain chemotherapeutics and
radiotherapy. Therefore, MTs may be of utility in diagnosis and management of patients with benign and malignant
lesions of the thyroid.
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Thyroid cancer is regarded as the most common cancer
of the endocrine organs and among all cancers it
accounts approximately up to 2.5% of all malignancies
[1,2]. Although, the death rates remain relatively low,
there is a growing trend towards higher incidence of thy-
roid cancer which might not be explained by progress in
detection of even relatively small thyroid cancers [1,3,4].
The majority of cancers of this organ develop from fol-
licular epithelial cells and due to their morphology and
biology are divided grossly into two groups. The first
group, the well differentiated thyroid cancers, which
include the papillary thyroid carcinoma (PTC) and the fol-
licular thyroid carcinoma (FTC) are usually slow growing,
characterized by iodine intake and susceptible to TSH-
suppressive therapy [5-7]. The PTC accounts for approxi-
mately up to 80% of thyroid tumours, whereas the FTC
accounts for 5-15% of diagnosed thyroid malignancies [8].
These cancers are usually curable utilizing combined sur-
gical and radioiodine therapy in contrast to the anaplastic
thyroid cancer (ATC), which represents the poorly differ-
entiated thyroid cancers [7]. ATC comprises only 1-2% of
all diagnosed thyroid malignancies, but is characterized by* Correspondence: piotr.dziegiel@am.wroc.pl
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reproduction in any medium, provided the orrapid and invasive growth resulting in fulminant disease
course and poor outcome [7,9]. In thyroid, approximately
5% of thyroid malignancies are diagnosed as medullary
carcinoma, which in turn originates from the parafollicu-
lar C cells [7].
All the above mentioned histological variants of thyroid
carcinomas may be easily distinguished upon histopatho-
logical examination, however in case of FTC problems
may occur in distinguishing these tumors from benign fol-
licular adenomas (FA) and follicular variants of PTC
(FVPTC) [6]. In case of FTC and FA the differential diag-
nosis is made by identification of signs of invasiveness into
the tumour capsule in numerous serial hematoxyline
and eosine stained slides. This renders the fine-needle
aspirates (FNA) of thyroid follicular nodules useless
for diagnostic purposes and biopsies not allowing for
determination of the lesions malignant potential are
determined as of indeterminate significance [5]. Up to
40% of FNA are regarded as indeterminate and subse-
quently the majority of the patients undergo surgery,
but only the minority of the resected thyroid nodules are
classified as malignant [10-14]. Moreover, no immunohis-
tochemical markers of invasiveness in FNA have been so
far discovered [5,15]. Molecular testing of FNA and
resected thyroid specimens may be of value, but none of
the recently discovered mutations in thyroid tissue is
widely used in the clinical practice [7,16].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ter understanding of the biology of thyroid tumours. It
seems that metallothioneins (MTs), due to their charac-
teristic properties may help in the differential diagnosis
of thyroid tumours and patients management. This re-
view presents the current knowledge regarding their ex-
pression in benign, as well as malignant thyroid lesions.
Metallothionein structure, synthesis and biological
functions
MTs are low molecular weight proteins (6-7kDa), which
are expressed in almost all types of organisms [17-19].
MTs were first isolated in 1957 from horse renal cortex
and since then our knowledge concerning these highly
conserved proteins have evolved [18,20]. All MTs posses
a highly conserved amino acid sequence and MTs iso-
lated from different animal species show little structural
changes. A single MT molecule consists of 61-68 amino
acids, depending on the isoform, where up to one third
of proteins sequence is composed of cysteine (Cys) resi-
dues [17,21]. Interestingly, this residues are organized in
typical tandem sequences, with up to two other amino
acids occurring between two cysteins [21]. Due to such
high cysteine content, MT possess the ability to bind up
to seven bivalent metal ions, such as zinc, copper, mer-
cury, lead [19], Moreover, MTs may bind up to twelve
univalent metal ions [19,22].
In the overall structure of MTs two domains have been
recognized, the domain α and β [23]. The domain α
comprises amino acids 31-68 and is located on the C-
terminal edge, whereas the N-terminal domain β com-
prises amino acids 1-30 [20]. The latter due to its highest
antigencity is used for production of antibodies, but due
to high homology of particular MT isoforms, the utility of
such obtained antibodies in distinguishing particular MT
isoforms is therefore highly limited [20,24,25]. Although,
MTs form a homogenous group of proteins (according to
their amino acid sequence and overall structure leading to
charge differences), four principal isoforms could be distin-
guished: MT-1, MT-2, MT-3 and MT-4 [26]. Most of our
knowledge concerning MTs biology stems from research
directed on examination of the MT-1 and MT-2 isoforms
(MT-1/2), which are ubiquitously expressed in almost all
cells of the organism [27]. Expression of MT-3 at first
seemed to be more specific and restricted only to neurons
and was first isolated from rat brain extracts suffering to
experimental Alzheimer disease [28-30]. MT-3 is also
known under the synonym growth inhibitory factor (GIF)
as it experimentally blocked the regeneration of neurons in
injured nervous tissue [30]. Recent studies have brought
more insights into the biology of this protein, as it
was also found to be expressed in some normal tis-
sues as well as in different tumour types [31-37]. The
expression of MT-4 seems to be restricted only tosquamous epithelium of the skin and upper parts of
the alimentary tract [38].
MTs are encoded by 17 genes located within the
16q13 region, from which 13 code for MT-1, two for
MT-2 and one gene each coding for MT-3 and MT-4
[26,38,39]. However, at least 10 genes code for functional
MT proteins: MT-1A, MT-1B, MT-1E, MT-1F, MT-1G,
MT-1H, MT-1X, MT-2A, MT-3 and MT-4 [24,26].
Beside the functional isoforms, there were also seven
non-functional isoforms identified: MT-1C, MT-1D,
MT-1I, MT-1J, MT-1K, MT-1L and MT-2B [26,40]. MTs
were found to be localized in cells cytoplasm, as well as
in cell nucleus [20,41]. Isoforms of the MT-1 and MT-2
family were shown to be induced by several substances
and agents e.g. heavy metals, steroids, cytokines, growth
factors and free radicals [42-46]. Zinc ion seems to rep-
resent the natural biological compound responsible for
the induction of MTs expression. Zinc ions bind to the
metal response element-binding transcription factor
(MTF-1), which interacts via its zinc finger domains
with a particular DNA region - the so called metal re-
sponse element (MRE). Binding of MTF-1 to MRE results
in initiation of MT-1/2 gene transcription [47-49]. Metal
ions, other than zinc, induce MT-1/2 expression inde-
pendently of the binding to the MTF-1 transcription fac-
tor as they may not activate this protein. However, these
metal ions possess higher affinity to MT-1/2 proteins as
compared to zinc ions, what results with the release of the
latter to the cytoplasm. As result, free zinc ions bind to
the MTF-1, what activates the transcription of MT-1/2
genes [50-52]. Similar mechanism is observed during oxi-
dative stress, in which MTs oxidation by hydrogen perox-
ide (H202) leads to release of zinc ions from these proteins
[53,54]. Regulation of MTs expression by glucocorticoid
hormones is regulated independently of the above men-
tioned mechanism, as glucocorticoid receptors bind to
the specific regulatory sequence (GRE; glucocorticoid
response element) in the promoter region of MTs genes
activating their transcription [27,55]. MTs expression may
be also induced during stress conditions via the antioxi-
dant response element (ARE) [17,56,57].
Although, MT-3 shows approximately 70% sequence
similarity to other MTs, however there are some differ-
ences in its structure, what might reflect its functional
diversity in comparison to other MTs. MT-3 posses a
glutamate-rich hexapeptide near the C-terminus and con-
tains a CPCP (Cys-Pro-Cys-Pro) motif (amino acids 6-9),
which is absent in other MTs [29,58]. This might be
reflected by the unique growth inhibitory role of MT-3,
not apparent in other MTs [28-30,58].
Metallothioneins in neoplasia
Lines of evidence point to significant role of MTs of the
MT-1 and MT-2 isoforms in development and progression
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metal binding properties of MTs, these proteins may act as
possible zinc ions donors for zinc-dependent enzymes and
transcription factors, which play crucial role in processes
such as replication, transcription and translation [18,61]. It
was shown, that in inactive cells (G0 phase) MTs can be
detected in the cytoplasm, whereas in cells undergoing div-
ision MTs are shifted to the nucleus. In addition, the high
cytoplasmic expression of MTs is noted at the end of G1
phase and at the G1/S threshold, while the highest MTs
concentration in cell nucleus was noted in the S and G2
phases [62,63]. The translocation of MTs into the nucleus
during G1/S phase in tumour cells suggests that MTs facil-
itates cell proliferation by donating zinc ions to various
transcription factors. Moreover, numerous reports based
on immunohistochemical methods seemed to confirm the
results obtained in vitro suggesting the role o MTs in cell
cycle regulation, as MTs expression was detected in the
cell cytoplasm and nucleus in organs undergoing growth
or regeneration (e.g. liver, kidney and parabasal cells of
stratified epithelium) [64-67]. In addition, MTs overexpres-
sion is frequently observed in various malignancies (epithe-
lial as well as mesenchymal tumours) and in some cases
increased with growing malignancy grade of those tumours
[20,24,66-75]. Lines of evidence suggest, that MTs may
diminish the suppressor function of the p53 protein lead-
ing to uncontrolled growth and proliferation [61,76].
Numerous experimental data have, shown a positive
correlation of MT expression and Ki-67 or PCNA
(proliferating cell nuclear antigen) antigens in human
tumour tissues, supporting the pro-proliferative role
of MTs [24,25,59,68,69,77,78].
Higher expression of MTs in human tumours was also
linked to increased chemoresistance of some tumour
types (e.g. gastric, ovarian, breast cancer), as it levels
increased after chemotherapy with agents such as cis-
platin, bleomycin, irinotecan or cyclophosphamide
[41,79-81]. Due to the structure of MTs, they may
diminish the effects of agents inducing the oxidative
stress (daunorubicin, doxorubicin), in mechanism in-
volving inactivation of free radicals [20,82]. Thanks to
the high affinity of MTs to metal ions, these proteins may
also inactivate alkylating drugs, characterized by cytotoxic
effects dependent on heavy metal compounds (e.g. cis-
platin, carboplatin) [83]. Several studies have shown that
MTs may mediate cancer cells chemoresistance in human
malignant tumours characterized by MTs overexpression
[79,81,84-86]. Moreover, free radicals scavenging proper-
ties MTs may also take part in cancer cells resistance to
radiotherapy [87].
Most of the studies have revealed, that MT-1/2 over-
expression in malignant cells is associated with poor
survival of patients with e.g. non-small cell lung cancer,
intrahepatic cholangiocarcionoma, synovial sarcoma, renalcancer or melanoma [24,70,71,88-90]. However, some of
the studies have showed that MTs in some tumour types
do not yield any prognostic significance, or - in some case
- were even associated with patients better prognosis
[72,91]. Interestingly, in some studies MT-1G (hepatocel-
lular and papillary thyroid cancer), MT-1F (colorectal
cancer) and MT-3 (gastric and esophageal cancer) iso-
form were regarded as potent tumour suppressors
[92-97]. In spite of many efforts, the role of MT-3 in neo-
plastic disease remains ambiguous and the results of the
studies were frequently inconsistent [31,32,36,37,98,99].
Therefore it seems, that the role of particular metallothio-
nein isoforms differ significantly and the utilization of
MTs as potent prognostic factors in human cancers
requires further research.
Metallothionein expression in thyroid tissues
First study regarding MTs expression in human thyroid
tissue was performed by Nartney et al. in 1987, who
used a polyclonal rabbit anti-MT antibody to examine
the expression levels of MTs in surgically resected
tumour samples and normal thyroid tissue biopsied from
autopsy cases [100]. This pilot study revealed that in
paraffin embedded tissues of normal thyroid, only 20%
of analyzed cases expressed MTs in the nucleus of
follicular thyroid cells, whereas a nuclear-cytoplasmic
expression pattern of MT was noted in majority of the
surgically resected tumour samples (91%) [100]. The
results obtained by Nartney et al. regarding MTs expres-
sion in normal thyroid tissues were not in accordance
with the results obtained by other studies, which showed
that MTs expression is mostly downregulated in thyroid
cancers when compared to normal thyroid follicular cells
or benign lesions of the thyroid e.g. nodular goiter
(Figure 1) [15,92,101,102]. These studies were performed
either on paraffin-embedded tissues using immunohisto-
chemistry or on fresh frozen material utilizing expres-
sion microarrays or real-time PCR. The latter allowed
to distinguish the expression of particular functional
MTs isoforms - data not possible to obtain with currently
available antibodies due to the homogenous structure of
MTs isoforms [92,101,102].
The microarray studies identified MT-1G gene expres-
sion as downregulated in PTC and FTC, supporting
recent reports of MT-1G suppressor role in human
colon and hepatocellular carcinoma [91-93,101,102].
Lines of evidence suggest that hypermethylation of gene
promoters occurs frequently in thyroid cancers and may
be responsible for altered expression of sodium-iodide
symporter (NIS), proteins associated with adhesion or
cell cycle [103-105]. Moreover, treatment of thyroid
cancer cell lines with demethylating agents could restore
the dedifferentiation of thyroid cancer cell lines and their
ability to iodide uptake [105]. The decreased expression of
Figure 1 Differentiated nyclear cytoplasmic MT-1/2 expression in normal thyroid cells (A), nodular goiter (B), follicular adenoma (C),
follicular carcinoma (D), papillary carcinoma (E) and medullary carcinoma (F). Magnification ×200.
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the CpG islands, but not the loss of heterozygosity (LOH)
[103]. This observations were also confirmed on cell lines
derived from human PTCs: NPA-87 (poorly differen-
tiated), K1 and K2 (well-differentiated) [103,106,107]. The
treatment of K2 cell line, which showed the highest
level of methylation, with demethylating agent 5-aza-
2’-deoxycytidene and/or trichostatin A (a histone dea-
cetylase inhibitor) induced the higher expression level
of MT-1G [103]. Similar results were described with
the K1 cell line [92].
Beside the MT-1G, also MT-1H and MT-1X were
shown to be downregulated in human PTC and FTC
[92]. Also in the study of Finn et al., it was demonstrated
that in PTCs with classic morphology, as well as in
the FVPTCs, MTs expression was downregulated what
points to a potential application of MTs as markers of thy-
roid malignancy [101]. Nevertheless, also in this aspectthe biological significance of the above mentioned findings
requires further research.
Biological significance of MTs expression in thyroid
cancers
The biological importance of MTs expression was only
assessed in relation to the MT-1G isoform in the study
of Ferrario et al., in which the expression of this isoform
was restored in the K1 thyroid papillary cancer cell line
with use of a MT-1G-myc expression plasmid [92].
MT-1G introduction into the K1 cell line resulted in
reduced growth rate in respect to control cells subse-
quently leading to formation of smaller colonies. The
suppressory role of MT-1G was additionally con-
firmed in vivo in athymic nude mice, as K1 cells with
MT-1G expression yielded reduced tumour growth as
compared to control cells [92]. Downregulation of MTs in
PTC may be also partly responsible for decreased
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tumour type, what might contribute to the carcinogenesis
process [108,109].
Impact of MTs expression on carcinogenesis of thyroid
cancer was also analysed in both studies of Liu et al.
with regard to papillary (KAT5 cells) and anaplastic
thyroid cancer (ARO cell line) [110,111]. In both studies
the cell lines were subjected to treatment with cadmium
ions (a potent inductor of MTs expression), in order to
examine the impact of MTs isoforms on carcinogenesis.
Cadmium treatment led to the induction of MT-1 and
MT-2 isoforms in both cell lines, although differences in
MT profile were observed [110,111]. In the KAT5 cells,
the MT-1G and MT-2A levels were identified as being the
most abundant isoforms upon cadmium treatment,
whereas in the ARO cell line additionally the MT-1A,
MT-1F, MT-1H, MT-1X were identified as the main func-
tional isoforms [110,111]. Both studies have shown that
induction of those isoforms was accompanied by alter-
ation in the cell cycle leading to increase of proportion of
cells in the S and G2-M phase and decrease in the propor-
tion of cells in the G0/G1 phase [110,111]. Moreover, cad-
mium treatment resulted also in rise of calcium ions
influx and led to a moderate rise in the phoshorylated
ERK1/2 (extracellular signal-regulated kinase), both pro-
cesses capable of stimulating cells proliferation [112]. Al-
though, it was shown that the expression of MT-1G may
alter proliferative response of KAT5 cells, the results of
both studies should be taken with caution, because the
study design did not allow clear assessment of MTs role in
the observed cell cycle alterations [92,110,111]. Moreover,
in our own study we did not observe any significant
correlation between the expression of the MT-1/2 and
the proliferation antigen Ki-67 in the series of PTC
and FTC cases [15].
Clinical significance of MTs in thyroid
Although, the prognostic significance of MTs expression
in thyroid cancer remains to be clarified, some of the
obtained results may have potential to be to applied in
clinical practice. Recent advance in molecular testing of
thyroid carcinomas led to the identification of genes
altered in particular type of the thyroid cancer [3,5,9,16].
It has become apparent that PTC and FTC harbour
different mutations. PTC is characterized by the muta-
tions in the RAS and BRAF genes as well as by rearrange-
ments of the RET/PTC genes capable of activating the
mitogen activated kinase (MAPK) pathway. In FTC altera-
tions in the RAS gene and PAX8/PPARγ rearrangements
were identified in majority of the cases [16]. However,
these mutations were also shown to occur in benign thy-
roid lesions. This fact, on one hand confirms the multistep
carcinogenesis process in the thyroid, but on the other
may render difficulties in introducing these new findingsinto clinical practice [7]. MTs expression shown as down-
regulated in majority of the thyroid cancer studies, could
be used as an ancillary marker helping in differential diag-
nosis of indeterminate FNA or surgical specimens of thy-
roid lesions [15,92,101-103]. We have recently shown that
immunohistochemical examination of MT-1/2 expression
may be of use in differentiating FA from FTC, which are
impossible to distinguish in FNA examination [6,8]. The
higher expression of MT-1/2 observed in FTC as com-
pared to FA may be of clinical importance, although this
finding must be confirmed on a larger patients cohort
with establishing proper cut-off points for the diagnosis
[15]. Moreover, the pronounced expression of MT-1/2 in
FTC may be linked to resistance to radiotherapy.
Conclusions
MTs due to their wide functional properties, potentially
associated with progression of majority of human can-
cers may pose an interesting point of research in relation
to human malignant thyroid lesions.
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